PDS Biotech Appoints John Dawson, Deborah Ramsdell and Bruce Wendel to Board

By Public Technologies
  • PDS Biotech appointed former Oxford Biomedica CEO John Dawson to its board, effective October 18, 2026.
  • Fellow appointee Deborah Ramsdell is CEO of Pluvia Biotech, having previously led Phoenicis Therapeutics and Valerion Therapeutics.
  • Bruce Wendel also joined the board; he previously served as executive vice president of corporate development at Bristol-Myers Squibb.
  • Stephen Glover and Kamil Ali-Jackson resigned from the board, effective October 18, 2026.
  • Gregory Freitag and Otis Brawley also stepped down on the same date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200800PRIMZONEFULLFEED9849048) on October 20, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk